Source and recovered plasma is the starting material used to manufacture lifesaving therapies. The manufacturing process is known as fractionation. Proteins are separated through this process to create a number of plasma protein therapies. This process is carried out using well-established purification methods such as precipitation, centrifugation, separation, and filtration.
Plasma is pooled and processed through a process called "fractionation" that employs time, temperature, pH, and alcohol concentrations to extract specific therapeutic proteins. These are then subjected to various purification methods and viral inactivation and removal processes to further ensure their safety and efficacy. Preparing a therapy often takes from seven to twelve months between donation and final product release. This sets the production of plasma protein therapies apart from chemical pharmaceuticals and other biologics whose manufacturing processes are much more condensed and whose direct manufacturing costs are a significantly smaller portion of the overall cost.
In addition, fractionators invest substantially in research and technologies to increase the quality of proteins extracted from plasma, known as the "yield," and create new and more effective therapies.